OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS
Cytovance Capabilities Update October 2026: Large Molecule
Move biologics from research and development toward commercialization with integrated development, analytics, scalable GMP manufacturing, and early-phase fill-finish capabilities.
Lonza Capabilities Update October 2026: Large Molecule
Ben Neunstoecklin, Director of Commercial Development, provides an overview of biologics drug substance manufacturing capabilities and global network capacity that supports customer programs from development through commercial supply.
Novartis Capabilities Update October 2026: Large Molecule
Reliable biologics manufacturing starts with experienced teams, proven tech transfer, and global capacity that scales from clinic to commercial.
Coriolis Pharma Capabilities Update October 2026: Large Molecule
Integrated drug product development helps biopharma teams identify risks early, optimize formulation and manufacturing, and create stable, scalable biologics ready for clinical and commercial success.
3PBiovian Capabilities Update October 2026: Large Molecule
Integrated CDMO services for biologics and advanced therapies, offering plasmid DNA, viral vectors, fill-finish, and scalable manufacturing from development through commercialization.
Rentschler Biopharma Capabilities Update July 2026: Large Molecule
At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing.
Avid Bioservices Capabilities Update July 2026: Large Molecule
Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.
Samsung Biologics Capabilities Update July 2026: Large Molecule
We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.
KBI BioPharma Capabilities Update July 2026: Large Molecule
Combining targeted transposon tech with stable bulk pool generation accelerates cell line development, enabling early material production and fast-tracking candidate selection for clinical entry.
AbbVie Capabilities Update July 2026: Large Molecule
Integrated manufacturing networks de-risk biopharmaceutical scale-up. Flexible mammalian platforms and advanced ADC conjugation ensure strict quality standards and long-term commercial supply.
Resilience Capabilities Update May 2026: Large Molecule
An integrated network unites biologics, cell therapy, and drug product with digital systems and teams to speed tech transfer, scale reliably, and ensure delivery from development to commercial.
Rentschler Biopharma Capabilities Update May 2026: Large Molecule
Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects.
Samsung Biologics Capabilities Update May 2026: Large Molecule
Watch this on-demand session to explore the future of global biologics manufacturing, dual-sourcing strategies, and next-generation expansion plans in advanced therapies.
Rezon Bio Capabilities Update May 2026: Large Molecule
Discover how tailored biologics development strategies can improve scalability, reduce tech transfer risk, and create more reliable pathways from early development to commercial supply.
Alcami Capabilities Update May 2026: Large Molecule
Watch this on-demand session to learn risk-based strategies for optimizing biologic drug substance-to-product transitions while minimizing aggregation and process stress.
Cytovance Biologics Capabilities Update March 2026: Large Molecule
How a seasoned development and manufacturing team blends technical depth, reliability, and flexible support to advance large‑molecule programs amid shifting timelines, costs, and regulatory demands.
Fujifilm Biotechnologies Capabilities Update March 2026: Large Molecule
An overview of manufacturing strategies and scaling options shows how aligned systems, smart planning, and flexible models support biologics from early development to commercialization.
ProBio Capabilities Update March 2026: Large Molecule
A new Center of Excellence expands capacity for genetic‑medicine programs with upgraded facilities, streamlined workflows, and early‑stage services that support readiness for PD and IND milestones.
Boehringer Ingelheim Capabilities Update March 2026: Large Molecule
Integrated culture and fermentation systems streamline development, improve scalability, and strengthen continuity throughout the lifecycle of complex biopharmaceutical programs.
Leveraging Advanced Tech, Proven Expertise From Cell Line Development And Beyond
Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.
Cytovance Capacity Update July 2024: Large Molecule Development
Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?